Results 191 to 200 of about 171,444 (265)

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Incidence of BK Virus in HIV-positive Kidney Transplant Recipients: Case Series From South Africa. [PDF]

Transplant Direct
Bertels L, Manning K, Redd AD, Barday Z, Muller E.   +4 more
europepmc   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review. [PDF]

Front Med (Lausanne)
Phongphithakchai A, Klangbud WK, Srithongkul T, Raksasuk S, Chatatikun M.   +4 more
europepmc   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Unveiling the silent burden: high prevalence of occult nephropathies in radical nephrectomy specimens. [PDF]

Clin Kidney J
Fenoglio R, Mantovani E, Cortazzi S, Barreca A, Graziano M, Bardari F, Sciascia S, Roccatello D.   +7 more
europepmc   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Analysis of Circulating and Urinary Levels of hsa-miRNA-770-5p in Diabetic Nephropathy. [PDF]

Biomolecules
Nikolov D, Nikolov G, Geneva-Popova M, Popova-Belova S, Naydenov M, Karusheva MG.   +5 more
europepmc   +1 more source

Refining the Genetic Contribution to Type 2 Diabetes Subtypes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Type 2 diabetes (T2D) is a complex and highly heterogeneous disease driven in part by genetic predisposition and can be stratified into clinical subgroups to aid disease management. We recently grouped T2D subjects in the Qatar Biobank (QBB) cohort into Severe Insulin‐Deficient Diabetes (SIDD), Severe Insulin‐Resistant Diabetes ...
Nayra M. Al‐Thani, Salman M. Toor, Umm‐Kulthum Ismail Umlai, Usama Aliyu, Karsten Suhre, Omar M. E. Albagha   +5 more
wiley   +1 more source

Growth Differentiation Factor-15 as a Biomarker of Diabetic Complications in Patients with Type 2 Diabetes. [PDF]

J Clin Med
Nikolova D, Yordanova S, Kamenov Z, Hristova J, Gateva AT.   +4 more
europepmc   +1 more source